Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | TYK2 | P29597 | 2/20 | 0.33 |
| ▸ | JAK3 | P52333 | 2/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25604082 | 0.81 | JAK2 (0.32) | JAK2TYK2JAK3JAK1KDM5B | |
| SCHEMBL21501996 | 0.80 | ACHE (0.33) | — | |
| SCHEMBL22541671 | 0.80 | — | — | |
| SCHEMBL3760813 | 0.79 | KDM5A (0.32) | JAK2TYK2JAK3KDM5B | |
| SCHEMBL2612382 | 0.78 | JAK2 (0.34) | JAK2TYK2JAK3JAK1KDM5B | |
| SCHEMBL3765275 | 0.76 | NPC1 (0.36) | JAK2TYK2JAK3JAK1 | |
| SCHEMBL4762523 | 0.76 | ESR1 (0.34) | JAK2TYK2JAK3KDM5B | |
| SCHEMBL21672546 | 0.76 | GABRA1 (0.50) | JAK2TYK2JAK3JAK1 | |
| SCHEMBL2806055 | 0.76 | JAK2 (0.33) | JAK2TYK2JAK3JAK1KDM5B | |
| SCHEMBL19121346 | 0.75 | CTSD (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158025-A1 | GALACTOKINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH | 2023-05-25 | — | — | US | disclosed |
| US-20230158025-A1 | GALACTOKINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158025-A1 | GALACTOKINASE INHIBITORS | GALK1, GCK, GCKR | JAK2 4298/4885TYK2 775/4885JAK3 3890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.